WCLC 2025 - Posters & ePosters-P3.12.18 Vebreltinib Plus EGFR-TKI in EGFR-Mutated NSCLC With MET Amplification And/Or Overexpression After Failure on EGFR-TKI: A Retrospective Study

P3.12.18 Vebreltinib Plus EGFR-TKI in EGFR-Mutated NSCLC With MET Amplification And/Or Overexpression After Failure on EGFR-TKI: A Retrospective Study

Back to course

Asset Subtitle

HaiBo Wang

Meta Tag

Speaker HaiBo Wang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy